Evidence map›Paper›PMID 42712348›Full record

ArticleBMJ digital health & AI2026

In vivo clinical effectiveness of artificial intelligence screening for acute coronary syndrome: testing real-world performance.

Gabrielle Bunney, Kate Miller, Keejeong Ryu, Anna Graber-Naidich, Alexander Wessels, Melissa Pasao, Marium Rizvi, Ian Brown, Maame Yaa A B Yiadom

Abstract read
In one paragraph

Article in BMJ digital health & AI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gabrielle BunneyDepartment of Emergency Medicine, Stanofrd University, Palo Alto, California, USA.ORCID 0000-0002-6120-9997
Kate MillerQuantitative Sciences Unit, Stanofrd University, Palo Alto, California, USA.
Keejeong RyuQuantitative Sciences Unit, Stanofrd University, Palo Alto, California, USA.
Anna Graber-NaidichQuantitative Sciences Unit, Stanofrd University, Palo Alto, California, USA.
Alexander WesselsTechnology and Digital Solutions, Stanford Healthcare, Palo Alto, California, USA.
Melissa PasaoDepartment of Emergency Medicine, Stanofrd University, Palo Alto, California, USA.
Marium RizviDepartment of Emergency Medicine, Stanofrd University, Palo Alto, California, USA.
Ian BrownDepartment of Emergency Medicine, Stanofrd University, Palo Alto, California, USA.
Maame Yaa A B YiadomDepartment of Emergency Medicine, Stanofrd University, Palo Alto, California, USA.

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Using Predictive Modeling for Acute Coronary Syndrome Screening to Improve Timely Diagnosis and Mortality for STEMIR01HL171403 · NHLBI · STANFORD UNIVERSITY · PI Maame Yaa A.B. Yiadom · 2024 to 2026
$2.1M
NCATS NIH HHS UL1 TR003142NHLBI NIH HHS R01 HL171403
6 · The paper itself

Abstract

Objective: Many predictive models are being developed, but few are deployed in clinical care. Hence, model performance within live real-world care is often not known. We trained a predictive model (in vitro) to (1) estimate patients' risk of acute coronary syndrome (ACS) on arrival to the emergency department (ED) and (2) identify those with highest risk for ST-segment myocardial infarction (STEMI) to receive an early ECG. We embedded this model into clinical care as clinical decision support (CDS) and using dynamic real-world data (in vivo), ran a silent pilot. We aimed to test the CDS's replication of the original model's screening performance and compare to standard of care screening by human staff. Methods and analysis: The CDS prospectively assessed each patient arriving in the ED between November 2023 and April 2024. It calculated each patient's risk for ACS, recorded a decision about whether the patient should receive an early ECG and was programmed to not exceed the total number of ECGs performed in human practice, approximately 33%. We used raw agreement and Cohen's Kappa to compare the screening decisions of the in vivo CDS and original in vitro model. We then measured sensitivity for ACS, our primary outcome, and specificity, which we compared between the CDS's and human screening decisions. Results: 32 346 visits were seen in the ED and processed by the CDS. 1.0% had ACS and 0.1% STEMI. Raw agreement between the CDS and original model was 96.8%, and Kappa was 91.2% (95% CI 90.7% to 91.8%). Sensitivity for ACS was 81.7% (95% CI 77.1% to 85.8%) in CDS versus 80.2% (95% CI 75.4% to 84.4%) observed in humans. Specificity for ACS was 67.3% (95% CI 66.8% to 67.9%) versus 67.4% (95% CI 66.9 to 67.9%), respectively. Conclusion: We found very good raw agreement and Kappa scores between the CDS and original model. Sensitivity and specificity between the CDS and human practice did not differ. This suggests that, when CDS is deployed independent of human decision-making, we can expect very high, although not perfect, performance replication. These differences need to be quantified and considered to estimate the real-world impact of models before deployment.

Indexed as

Artificial intelligenceEvidence-Based Emergency MedicineImplementation Science

Identifiers

PMID42712348
PMCPMC13528385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.